Early Detection and Diagnosis

You have full text access to this OnlineOpen article

Novel markers for poor prognosis in head and neck cancer

  1. David Chin1,4,5,†,*,
  2. Glen M. Boyle1,
  3. Rebecca M. Williams3,
  4. Kaltin Ferguson1,
  5. Nirmala Pandeya2,
  6. Julie Pedley1,
  7. Catherine M. Campbell3,
  8. David R. Theile4,
  9. Peter G. Parsons1,
  10. William B. Coman5

Article first published online: 21 OCT 2004

DOI: 10.1002/ijc.20608

Issue

International Journal of Cancer

International Journal of Cancer

Volume 113, Issue 5, pages 789–797, 20 February 2005

Additional Information

How to Cite

Chin, D., Boyle, G. M., Williams, R. M., Ferguson, K., Pandeya, N., Pedley, J., Campbell, C. M., Theile, D. R., Parsons, P. G. and Coman, W. B. (2005), Novel markers for poor prognosis in head and neck cancer. Int. J. Cancer, 113: 789–797. doi: 10.1002/ijc.20608

Author Information

  1. 1

    Melanoma Genomics Group, Queensland Institute of Medical Research, Herston, Brisbane, Queensland, Australia

  2. 2

    Cancer and Population Studies Group, Queensland Institute of Medical Research, Herston, Brisbane, Queensland, Australia

  3. 3

    Pathology Unit, University of Queensland, Princess Alexandra Hospital, Woollongabba, Brisbane, Queensland, Australia

  4. 4

    Plastic Surgery Unit, University of Queensland, Princess Alexandra Hospital, Woollongabba, Brisbane, Queensland, Australia

  5. 5

    Head and Neck Unit, University of Queensland, Princess Alexandra Hospital, Woollongabba, Brisbane, Queensland, Australia

  1. †

    Fax: +61-7-3845-3508

*Head and Neck Unit, University of Queensland, Princess Alexandra Hospital, Woollongabba, Brisbane, 4102, Queensland, Australia

Publication History

  1. Issue published online: 8 DEC 2004
  2. Article first published online: 21 OCT 2004
  3. Manuscript Accepted: 21 JUL 2004
  4. Manuscript Received: 19 MAR 2004

Funded by

  • Garnett-Passe and Rodney Williams Memorial Foundation Project Grant
  • University of Queensland Graduate Medical School Scholarship
  • Queensland Cancer Fund Clinical Fellowship

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (505K)

References

  • 1
    Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993; 54: 594–606.
    Direct Link:
  • 2
    American Cancer Society. Cancer facts and figures 2000. Atlanta: American Cancer Society, 2000.
  • 3
    Al Moustafa AE, Alaoui-Jamali MA, Batist G, Hernandez-Perez M, Serruya C, Alpert L, Black MJ, Sladek R, Foulkes WD. Identification of genes associated with head and neck carcinogenesis by cDNA microarray comparison between matched primary normal epithelial and squamous carcinoma cells. Oncogene 2002; 21: 2634–40.
  • 4
    Leethanakul C, Knezevic V, Patel V, Amornphimoltham P, Gillespie J, Shillitoe EJ, Emko P, Park MH, Emmert-Buck MR, Strausberg RL, Krizman DB, Gutkind JS. Gene discovery in oral squamous cell carcinoma through the Head and Neck Cancer Genome Anatomy Project: confirmation by microarray analysis. Oral Oncol 2003; 39: 248–58.
  • 5
    Warner GC, Reis PP, Makitie AA, Sukhai MA, Arora S, Jurisica I, Wells RA, Gullane P, Irish J, Kamel-Reid S. Current applications of microarrays in head and neck cancer research. Laryngoscope 2004; 114: 241–8.
    Direct Link:
  • 6
    Ginos MA, Page GP, Michalowicz BS, Patel KJ, Volker SE, Pambuccian SE, Ondrey FG, Adams GL, Gaffney PM. Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. Cancer Res 2004; 64: 55–63.
  • 7
    Bittner M, Butow R, DeRisi J. Expression analysis of RNA. In: BowtellD, SambrookJ, eds. DNA microarrays: a molecular cloning manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 2004. 101–288.
  • 8
    Ablett E, Whiteman DC, Boyle GM, Green AC, Parsons PG. Induction of metallothionein in human skin by routine exposure to sunlight: evidence for a systemic response and enhanced induction at certain body sites. J Invest Dermatol 2003; 120: 318–24.
  • 9
    Bouchet C, Hacene K, Martin PM, Becette V, Tubiana-Hulin M, Lasry S, Oglobine J, Spyratos F. Dissemination risk index based on plasminogen activator system components in primary breast cancer. J Clin Oncol 1999; 17: 3048–57.
  • 10
    Herszenyi L, Plebani M, Carraro P, De Paoli M, Roveroni G, Cardin R, Foschia F, Tulassay Z, Naccarato R, Farinati F. Proteases in gastrointestinal neoplastic diseases. Clin Chim Acta 2000; 291: 171–87.
  • 11
    Pasini FS, Brentani MM, Kowalski LP, Federico MH. Transforming growth factor beta1, urokinase-type plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in head and neck squamous carcinoma and normal adjacent mucosa. Head Neck 2001; 23: 725–32.
    Direct Link:
  • 12
    Kelm RJ Jr, Hair GA, Mann KG, Grant BW. Characterization of human osteoblast and megakaryocyte-derived osteonectin (SPARC). Blood 1992; 80: 3112–9.
  • 13
    Wrana JL, Overall CM, Sodek J. Regulation of the expression of a secreted acidic protein rich in cysteine (SPARC) in human fibroblasts by transforming growth factor beta. Comparison of transcriptional and post-transcriptional control with fibronectin and type I collagen. Eur J Biochem 1991; 197: 519–28.
    Direct Link:
  • 14
    Iruela-Arispe ML, Diglio CA, Sage EH. Modulation of extracellular matrix proteins by endothelial cells undergoing angiogenesis in vitro. Arterioscler Thromb 1991; 11: 805–15.
  • 15
    Reed MJ, Vernon RB, Abrass IB, Sage EH. TGF-beta 1 induces the expression of type I collagen and SPARC, and enhances contraction of collagen gels, by fibroblasts from young and aged donors. J Cell Physiol 1994; 158: 169–79.
    Direct Link:
  • 16
    Wrana JL, Kubota T, Zhang Q, Overall CM, Aubin JE, Butler WT, Sodek J. Regulation of transformation-sensitive secreted phosphoprotein (SPPI/osteopontin) expression by transforming growth factor-beta. Comparisons with expression of SPARC (secreted acidic cysteine-rich protein). Biochem J 1991; 273: 523–31.
  • 17
    Kato Y, Lewalle JM, Baba Y, Tsukuda M, Sakai N, Baba M, Kobayashi K, Koshika S, Nagashima Y, Frankenne F, Noel A, Foidart JM, et al. Induction of SPARC by VEGF in human vascular endothelial cells. Biochem Biophys Res Commun 2001; 287: 422–6.
  • 18
    Tremble PM, Lane TF, Sage EH, Werb Z. SPARC, a secreted protein associated with morphogenesis and tissue remodeling, induces expression of metalloproteinases in fibroblasts through a novel extracellular matrix-dependent pathway. J Cell Biol 1993; 121: 1433–44.
  • 19
    Goldblum SE, Ding X, Funk SE, Sage EH. SPARC (secreted protein acidic and rich in cysteine) regulates endothelial cell shape and barrier function. Proc Natl Acad Sci USA 1994; 91: 3448–52.
  • 20
    Porter PL, Sage EH, Lane TF, Funk SE, Gown AM. Distribution of SPARC in normal and neoplastic human tissue. J Histochem Cytochem 1995; 43: 791–800.
  • 21
    Porte H, Chastre E, Prevot S, Nordlinger B, Empereur S, Basset P, Chambon P, Gespach C. Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin-3 and BM-40/SPARC genes. Int J Cancer 1995; 64: 70–5.
    Direct Link:
  • 22
    Massi D, Franchi A, Borgognoni L, Reali UM, Santucci M. Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum Pathol 1999; 30: 339–44.
  • 23
    Tuck AB, Hota C, Chambers AF. Osteopontin(OPN)-induced increase in human mammary epithelial cell invasiveness is urokinase (uPA)-dependent. Breast Cancer Res Treat 2001; 70: 197–204.
  • 24
    Fisher JL, Field CL, Zhou H, Harris TL, Henderson MA, Choong PF. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases—a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases. Breast Cancer Res Treat 2000; 61: 1–12.
  • 25
    Boyle JO, Hakim J, Koch W, van der Riet P, Hruban RH, Roa RA, Correo R, Eby YJ, Ruppert JM, Sidransky D. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 1993; 53: 4477–80.
  • 26
    Sartor M, Steingrimsdottir H, Elamin F, Gaken J, Warnakulasuriya S, Partridge M, Thakker N, Johnson NW, Tavassoli M. Role of p16/MTS1, cyclin D1 and RB in primary oral cancer and oral cancer cell lines. Br J Cancer 1999; 80: 79–86.
  • 27
    Reed AL, Califano J, Cairns P, Westra WH, Jones RM, Koch W, Ahrendt S, Eby Y, Sewell D, Nawroz H, Bartek J, Sidransky D. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 1996; 56: 3630–3.
  • 28
    Taylor D, Koch WM, Zahurak M, Shah K, Sidransky D, Westra WH. Immunohistochemical detection of p53 protein accumulation in head and neck cancer: correlation with p53 gene alterations. Hum Pathol 1999; 30: 1221–5.
  • 29
    Yuen PW, Man M, Lam KY, Kwong YL. Clinicopathological significance of p16 gene expression in the surgical treatment of head and neck squamous cell carcinomas. J Clin Pathol 2002; 55: 58–60.
View Full Article (HTML) Get PDF (505K)